Cocrystal Pharma, Inc. Files Amendment to Annual Report

Ticker: COCP · Form: 10-K/A · Filed: Apr 17, 2024 · CIK: 1412486

Cocrystal Pharma, INC. 10-K/A Filing Summary
FieldDetail
CompanyCocrystal Pharma, INC. (COCP)
Form Type10-K/A
Filed DateApr 17, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: Cocrystal Pharma, COCP, 10-K/A, SEC Filing, Amendment

TL;DR

<b>Cocrystal Pharma, Inc. has filed an amendment to its 2023 annual report, confirming its status as a filer and its listing on Nasdaq.</b>

AI Summary

Cocrystal Pharma, Inc. (COCP) filed a Amended Annual Report (10-K/A) with the SEC on April 17, 2024. Cocrystal Pharma, Inc. filed an amendment (No. 1) to its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is registered under the standard industrial classification for Pharmaceutical Preparations [2834]. Cocrystal Pharma, Inc. is incorporated in Delaware and has its principal executive office in Bothell, WA. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol COCP. The filing indicates that Cocrystal Pharma, Inc. has submitted all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking Cocrystal Pharma, Inc., this filing contains several important signals. This amendment provides updated or corrected information for the fiscal year 2023, which is crucial for investors to have the most accurate financial and operational data. The confirmation of filing status and Nasdaq listing is important for maintaining regulatory compliance and investor confidence.

Risk Assessment

Risk Level: low — Cocrystal Pharma, Inc. shows low risk based on this filing. The filing is an amendment to a 10-K, indicating it's a routine update or correction rather than a response to a new, significant event, thus posing a low immediate risk.

Analyst Insight

Monitor future filings for any substantive changes or updates that may arise from this amendment.

Key Numbers

Key Players & Entities

FAQ

When did Cocrystal Pharma, Inc. file this 10-K/A?

Cocrystal Pharma, Inc. filed this Amended Annual Report (10-K/A) with the SEC on April 17, 2024.

What is a 10-K/A filing?

A 10-K/A is a amendment to a previously filed annual report, correcting or updating financial statements or disclosures. This particular 10-K/A was filed by Cocrystal Pharma, Inc. (COCP).

Where can I read the original 10-K/A filing from Cocrystal Pharma, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Cocrystal Pharma, Inc..

What are the key takeaways from Cocrystal Pharma, Inc.'s 10-K/A?

Cocrystal Pharma, Inc. filed this 10-K/A on April 17, 2024. Key takeaways: Cocrystal Pharma, Inc. filed an amendment (No. 1) to its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The company is registered under the standard industrial classification for Pharmaceutical Preparations [2834].. Cocrystal Pharma, Inc. is incorporated in Delaware and has its principal executive office in Bothell, WA..

Is Cocrystal Pharma, Inc. a risky investment based on this filing?

Based on this 10-K/A, Cocrystal Pharma, Inc. presents a relatively low-risk profile. The filing is an amendment to a 10-K, indicating it's a routine update or correction rather than a response to a new, significant event, thus posing a low immediate risk.

What should investors do after reading Cocrystal Pharma, Inc.'s 10-K/A?

Monitor future filings for any substantive changes or updates that may arise from this amendment. The overall sentiment from this filing is neutral.

How does Cocrystal Pharma, Inc. compare to its industry peers?

Cocrystal Pharma, Inc. operates within the Pharmaceutical Preparations industry, focusing on the development of antiviral therapeutics.

Are there regulatory concerns for Cocrystal Pharma, Inc.?

The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments.

Industry Context

Cocrystal Pharma, Inc. operates within the Pharmaceutical Preparations industry, focusing on the development of antiviral therapeutics.

Regulatory Implications

The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments.

What Investors Should Do

  1. Review the full amended 10-K filing for specific details on any changes or updates.
  2. Track Cocrystal Pharma's (COCP) stock performance and news releases following this filing.
  3. Assess the company's regulatory compliance based on its consistent filing history.

Key Dates

Year-Over-Year Comparison

This filing is an amendment (No. 1) to the original 10-K, indicating a correction or addition to the previously submitted annual report for the fiscal year ended December 31, 2023.

Filing Stats: 4,540 words · 18 min read · ~15 pages · Grade level 11.6 · Accepted 2024-04-17 17:00:25

Key Financial Figures

Filing Documents

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 3

EXECUTIVE COMPENSATION

Item 11. EXECUTIVE COMPENSATION 9

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 13

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 14

PRINCIPAL ACCOUNTANT FEES AND SERVICES

Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 15 PART IV 15

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 16

SIGNATURES

SIGNATURES 18 2 EXPLANATORY NOTE This Amendment No. 1 on Form 10-K/A (this "Amendment") amends our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"), as filed with the Securities and Exchange Commission (the "SEC") on March 28, 2024, solely to include the information required by and not included in Part III of the 2023 Form 10-K because we do not intend to filed our definitive proxy statement within 120 days of the end of our fiscal year ended December 31, 2023. In connection with the filing of this Amendment and pursuant to the rules of the SEC, we are including new certifications of our principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 with this Amendment. Accordingly, Item 15 of Part IV has also been amended to reflect the filing of these new certifications. Because no financial statements are contained within this Amendment, we are not filing currently dated certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Except as described above, no other changes have been made to the 2023 Form 10-K. The 2023 Form 10-K continues to speak as of the date of the 2023 Form 10-K, and we have not updated the disclosure contained therein to reflect any events which occurred at a date subsequent to the filing of the 2023 Form 10-K other than as expressly indicated in this Amendment. Unless the contact requires otherwise, the terms "Cocrystal," the "Company," "we," "us," and "our" refer to Cocrystal Pharma, Inc. PART III Item 10. Directors, Executive Officers, and Corporate Governance. The following is a list of our directors and executive officers. Name Age Position Sam Lee 64 Co-Chief Executive Officer, President James Martin 57 Co-Chief Executive Officer, Chief Financial Officer Roger Kornberg 76 Chairman and Director Phillip Frost 87 Director Fred Hassan 78 Director Anthony Japour 64 Director

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing